ALLMedicine™ Acquired Hemophilia A Center
Research & Reviews 110 results
The Journal of Obstetrics and Gynaecology Research; Nishi A, Muramatsu A et. al.
Jul 16th, 2021 - Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies that inhibit coagulation factor VIII. Pregnancy could be associated with AHA in younger women. Because of its rarity, the optimal management for pregnancy-related AHA...
Medicine Yamamoto M, Shindo M et. al.
Apr 22nd, 2021 - Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against factor VIII (FVIII). Hematological malignancies, especially lymphoid malignancies, are known to be underlying causes of AHA; however, thus far, there is no re...
Expert Review of Hematology; Franchini M, Schiavulli M et. al.
Mar 4th, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...
Thrombosis and Haemostasis; Takeyama M, Furukawa S et. al.
Mar 1st, 2021 - Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A...
The American Journal of Case Reports; Regino CA, Alvarez JC et. al.
Feb 18th, 2021 - BACKGROUND Acquired hemophilia is a bleeding disorder mediated by an autoimmune process, in which antibodies against clotting factors are developed. This is a rarely suspected complex condition in which the initial manifestations are spontaneous b...
Drugs 6 results see all →
Clinicaltrials.gov 4 results
Dec 12th, 2019 - This is a prospective randomized multi-center controlled pilot trial comparing the regimen of steroid with rituximab and steroid with cyclophosphamide to eradicate anti-factor VIII antibodies in Chinese patients with acquired hemophilia A. Patient...
Nov 23rd, 2018 - This is a prospective, single-arm, open-label clinical trial to evaluate the efficacy and safety the regimen of Bortezomib with rituximab as first-line treatment to eradicate anti-factor VIII antibodies in newly diagnosed acquired hemophilia A. Al...
Oct 23rd, 2017 - This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.
Feb 10th, 2017 - This is a prospective Phase II randomized multi-institutional controlled pilot trial comparing the regimen of single agent rituximab with 6 weeks cytotoxic therapy with oral cyclophosphamide to eradicate or suppress autoimmune anti-factor VIII ant...
News 11 results
Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.
May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.
Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.
Nov 23rd, 2015 - Trends-in-Medicine (access restricted) dug up details on the proposed CMS coverage restrictions for the Watchman left atrial appendage (LAA) closure device, which revealed that: The agency is likely to clarify its requirement that patients not be ...
Nov 15th, 2015 - Vial of Obizur Photo courtesy of Baxter International Inc. The European Commission (EC) has approved a recombinant porcine factor VIII (FVIII) product, Obizur, to treat bleeding episodes in adults with acquired hemophilia A caused by autoantibodie.